CERo Therapeutics Holdings Inc (CERO) Quote

Interesting float.....

I sold them at 04 last night right before the clothes… I'm gonna add more this morning

😂😂😂 Didn't win on this one?? Surprised lol 😂

Grabbed 5000 warrants at .03.  What are they really worth now?

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

June 17, 2025

https://ih.advfn.com/stock-market/NASDAQ/quantum-biopharma-QNTM/stock-news/96257758/quantum-biopharma-announces-first-person-with-mult

$CERO

halted, great move doubled in one trade, pure luck. Good luck everyone. From $10.80.

missed 🧨

I'm looking for $22.00🤩

ON FIRE!💥

CERO............................................https://stockcharts.com/h-sc/ui?s=CERO&p=W&b=5&g=0&id=p86431144783









........thx.......................lost intheshuffle............................

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.

CER-1236 is currently in Phase 1 clinical trials for AML. The first-in-human, multi-center, open label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. The two-part study has begun with dose escalation to determine highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK).

Chris Ehrlich, CERo CEO, commented, “Orphan Drug Designation underscores the importance of developing new treatments for AML, and the potential for CER-1236 to provide a new and differentiated approach toward treatment. We believe that we are at the forefront of innovation in immuno-oncology and are grateful for the recognition from FDA. We look forward to providing updates on our trial in the near term.”

The FDA's Orphan Drug program is designed to advance the development of drugs that treat a condition affecting 200,000 or fewer US patients annually. ODD status is given to medicinal products that represent a significant benefit over existing treatments and are intended for the treatment of a disease that is life-threatening or chronically debilitating. The ODD designation qualifies CERo and CER-1236 for certain incentives, which include FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the drug approval application fee and eligibility for seven years of marketing exclusivity.

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

SOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction.

The gross proceeds to CERo from the offering are expected to be up to $8 million, including $5 million expected to be received through the investment of securities at the first closing, and up to $3 million of cash that may be funded at one or more additional closings, at the election of the investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. The proceeds will also help to address current Nasdaq deficiencies around Shareholders Equity and extend cash on hand to maintain operations and extend runway.

“On the heels of our recent announcements anticipating the imminent dosing of our first AML patient at MD Anderson Cancer Center and the IND allowance in solid tumors, we are gratified by the support we have received from investors and look forward to continued execution and progress,” said Chris Ehrlich, Chief Executive Officer.

CERO, new 52 week low

CERO, new 52 week low

CERO under $2

@DOMH??? (What irony!!! I just had a Dominari PIZZA for lunch, over here in San Diego!!!)

Tell that to $DOMH wants to run $2.70s now 

CERO DILUTION CRASH AND BURN

CERO: Witty!!! (The MONSTER mystery about YOU, Dude, is why you don't have circa 3,000+ iHub FOLLOWERS by now!!! Seriously!!!)

From CERO $2.53 + 26% to HERO 

CERO READY TO BLAST OFF

CERO POST SPLIT BIO READY TO BEAST

CERO, new 52 week low

CERO new 52 week low

01/07/2025 19:50:00 CERO CERo Therapeutics Holdings Cmn NASDAQ
T1
https://www.nasdaqtrader.com/trader.aspx?id=tradehalts

WRONG BOARD!!! (Meant to say FUBO!!!)

yeah everyone is unloading as fast as they can huge volume falling price...glad for a change i didnt bite lol

CERO: Toilet flush!! (Maybe back up, later.)

yeah down that sux

What is the OS after the R/S

Almost chewed through the whole 260 mill OS!

Wow!!! CERo : 1 for 100 R/S: Therapeutics Holdings, Inc. Announces Reverse Stock Split

2025-01-06 08:00 ET - News Release


SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-one hundred reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 8, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Global Market (“Nasdaq”) as of the opening of trading on January 8, 2025. The CUSIP number of 71902K303 will be assigned to the Company’s Common Stock when the reverse stock split becomes effective.

CERO: It's moving!!

December 2nd is long gone and still nothing

Seriously let this go for goodness sakes, CERO deserves a medal for 5's and 6's , getting dizzy watching this for days and days let it go 

Time to break .07 on Thursday, then smash .085, onto .15 for more than a double from here at .0623 load those cheap shares !!!!

Wonder why this one doesn't move with 150, million share sold

Yep, chart looks good.

Looks good after the beat down from .20s

somethins brewin...

CERO could it be the next Hero .087 +'42%

L😂L

CERO...Took a loss here...All Out...Will watch for the Reverse Split...🥳

Or even yet they may be able to file for another 180-day extension beyond January 25, 2025 if they are granted from hearing panel.

No I found it, R/S has been voted in...after looking again in the 10Q a little harder....and just because it hasn't been activated on Dec 2 that it won't happen...could be any day now until January 15, 2025...they may hold off as long as they can before their 180 day extension is up to become compliant again.

8-K about the compliance 180 days: https://www.otcmarkets.com/filing/html?id=17917292&guid=T8Y-kWV46v3Th3h

10-Q filing: https://www.otcmarkets.com/filing/html?id=17988358&guid=T8Y-kWV46v3Th3h



NOTE 12 – Subsequent Events



On October 1, 2024, the Company’s Board of Directors granted Directors and Officers options to purchase up to 4.5 million shares of common stock for $0.10 per share. The grants have various vesting conditions, including time-based and performance-based terms. Additionally, on October 1, 2024, the exercise price of all other outstanding options granted under the 2024 Plan was adjusted to $0.10 per share, with all other terms of the original grant to remain without adjustment.



On October 23, 2024, the trading price for CERo common stock closed under $0.10 and was the tenth consecutive trading day to do so. On October 24, 2024, the Company received letter from the staff at The Nasdaq Global Market (“Nasdaq”) notifying the Company that, because its Common Stock had a closing bid price of $0.10 or less for ten consecutive trading days, it was no longer eligible to rely upon the 180-day cure period that commenced when the Company received notice in July 2024 that the closing bid price was below $1.00 for ten consecutive trading days and was scheduled to expire on January 15, 2025. In addition, on October 30, 2024, the Company received a letter from the staff at Nasdaq notifying the Company that it had not regained compliance with the continued listing requirement to maintain a minimum market value of $50,000,000 for its listed securities within the 180-day compliance period granted by Nasdaq in May 2024. Each such deficiency results in the commencement of delisting proceedings. However, the Company has requested a hearing from Nasdaq and plans to submit a plan to regain compliance with the listing requirements at such hearing.



On November 8, 2024, the Company consummated a purchase agreement with Keystone pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to $20.6 million of shares of Common Stock, subject to certain market conditions. The price of the shares purchased by Keystone under the ELOC is 90% of various volume-weighted average price (“VWAP”) and closing price-based formulae, and requires a waiver, should the selling price be below $0.01 per share.



On November 11. 2024, the Company’s stockholders approved a reverse stock split ranging from 1:25 to 1:150. On November 15, 2024, the Board of Directors authorized a reverse stock split ratio of 1:40, such reverse split is anticipated to be effective on or about December 2, 2024. Although such reverse stock split is expected to enable regaining compliance with the Bid Price Requirement, it is not intended to contribute to regaining compliance with the other Requirements.

On 10/18/24 DEF 14 A special meeting announcement for 11/11/24, the R/S is proposal no.1: https://www.otcmarkets.com/filing/html?id=17902016&guid=T8Y-kWV46v3Th3h
However, I looked on all 8-Ks and even the 10-Q after November 11, 2024 and I never seen anywhere what the results were nor could I find where the meeting was cancelled.

Are we headed for a R/S ? I certainly hope not. I know a lot of insiders have recently bought in here.

Your thoughts?

CERO...Added 079s here...🥳Trying to get another flip...

CERO...106...🥳...Took some for a flip...

georgie18

Member Level
Re: None

Friday, December 06, 2024 10:33:11 AM

Post#
667048
of 667240
CERO...13...-30%...Bidding .10/.11...Range if I can get some for a quick flip...🥳R/S coming here and Offering...

CERO...13...-30%...Bidding .10/.11...Range if I can get some for a quick flip...🥳